Last reviewed · How we verify
Anti-CD19 UCAR-T cells — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Anti-CD19 UCAR-T cells (Anti-CD19 UCAR-T cells) — Chongqing Precision Biotech Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-CD19 UCAR-T cells TARGET | Anti-CD19 UCAR-T cells | Chongqing Precision Biotech Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-CD19 UCAR-T cells CI watch — RSS
- Anti-CD19 UCAR-T cells CI watch — Atom
- Anti-CD19 UCAR-T cells CI watch — JSON
- Anti-CD19 UCAR-T cells alone — RSS
Cite this brief
Drug Landscape (2026). Anti-CD19 UCAR-T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cd19-ucar-t-cells. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab